Dr Komrokji on Ongoing Investigations With Luspatercept in MDS
November 3rd 2023Rami Komrokji, MD, discusses the benefit of agents such as luspatercept-aamt in patients with very low– to intermediate-risk myelodysplastic syndromes who have not received prior treatment with erythropoiesis-stimulating agents.
Luspatercept Approval Shifts Treatment Landscape of Anemia in Lower-Risk MDS
October 24th 2023Uwe Platzbecker, MD, discusses how to navigate decisions for the first-line treatment of anemia in patients with lower-risk MDS in light of luspatercept’s approval, expands on key data from the COMMANDS trial, and addresses potential concerns from clinicians who are uncertain about when to utilize this agent in the frontline setting in clinical practice.
Dr Platzbecker on the COMMANDS Trial in Lower-Risk MDS With Anemia
October 7th 2023Uwe Platzbecker, MD, discusses key findings from the phase 3 COMMANDS trial with luspatercept in patients with lower-risk myelodysplastic syndrome with anemia, as well as the clinical implications of FDA approval of luspatercept for patients in this population.
Luspatercept Broadens Lower-Risk MDS Treatment Landscape
September 25th 2023Guillermo Garcia-Manero, M, discusses key efficacy and safety findings from the COMMANDS trial; the significance of the FDA approval of luspatercept in patients with lower-risk MDS; and considerations for bringing this agent into clinical practice.
Dr Garcia-Manero on the Investigation of Luspatercept in Transfusion-Dependent MDS
September 12th 2023Guillermo Garcia-Manero, MD, discusses the investigation of luspatercept vs epoetin alfa in patients with erythropoiesis-stimulating agent-naïve, lower-risk myelodysplastic syndromes and disease-related anemia who requires red blood cell transfusions.